MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) today announced results of Health Economics and Outcomes Research (HEOR) analyses reinforcing the use of Aptiom® (eslicarbazepine acetate) as monotherapy or adjunctive therapy for partial-onset seizures at the 68th American Academy of Neurology (AAN) Annual Meeting in Vancouver, Canada. Additional results from a national survey quantified the impact of antiepileptic drug (AED) attributes on physician prescribing and the preferences of people with epilepsy. Data will be shared through multiple poster presentations at AAN.
